#182 - David Nutt: Psychedelics & Recreational Drugs

Episode Summary

Executive Summary: Peter Attia interviews psychiatrist-neuroscientist David Nutt on how to evaluate drugs by harm to users, harm to society, and addiction potential. They compare alcohol, tobacco, opioids, cocaine, methamphetamine, cannabis, ketamine, LSD, psilocybin, MDMA, and ibogaine, arguing that drug policy has often been driven by politics rather than evidence. The conversation emphasizes psychedelics’ therapeutic promise, especially for depression and addiction, and the need for better research and rational regulation.

Main Topics: A framework for judging drug harm (Priority: 5/5): Nutt explains a multi-criteria decision analysis that rates drugs across 16 harms: nine to the user and seven to society, allowing transparent comparisons beyond moral judgments. Alcohol, tobacco, and the mismatch between legality and harm (Priority: 5/5): Alcohol ranks as the most harmful overall because of societal damage, while tobacco is highly harmful but less socially destructive; both illustrate how legal status does not track true risk. Opioid crisis and fentanyl escalation (Priority: 5/5): They trace the opioid epidemic from overprescribing to dependence, black-market substitution, and fentanyl’s rise, emphasizing respiratory depression and the need for safer pain treatments. Psychedelics as medicines, not just intoxicants (Priority: 5/5): LSD, psilocybin, and MDMA are presented as among the least harmful drugs and as potentially transformative treatments for depression, PTSD, addiction, and end-of-life distress. Ketamine and ibogaine in depression and addiction (Priority: 4/5): Ketamine is discussed as a fast-acting but short-lived antidepressant with dependence risks, while ibogaine/noribogaine are explored as promising but cardiotoxic addiction treatments. Drug policy as politics and stigma (Priority: 4/5): Nutt argues that cannabis, LSD, MDMA, and psilocybin were restricted largely due to political pressure, media panic, and institutional incentives rather than balanced evidence. Psilocybin vs. escitalopram study and the future of psychedelic psychiatry (Priority: 5/5): They review the NEJM trial comparing psilocybin with Lexapro, highlighting comparable antidepressant efficacy and better tolerability signals, while debating how to interpret the results and move toward approval.

Key Arguments: A rational drug policy should compare harms to the user, harms to society, and addiction potential rather than relying on stigma or legality. Alcohol is the most harmful drug overall because its social harms exceed those of other substances, even though tobacco kills many people later in life. The opioid epidemic was amplified by overprescribing, then worsened by abrupt restriction, black-market substitution, and fentanyl’s potency. Cannabis research has been stunted by prohibition, preventing rigorous study of benefits and harms, especially in medical contexts. Classic psychedelics are among the least harmful drugs and may be the most promising for treating depression, addiction, and existential distress. LSD and psilocybin were historically studied extensively and showed therapeutic promise, especially for alcoholism, before political forces shut research down. Ketamine can rapidly improve depression but has short duration of benefit and significant abuse/toxicity risks at high or frequent doses. Ibogaine may help opioid withdrawal/addiction, but cardiac toxicity makes careful clinical study essential before broader use. The psilocybin vs. escitalopram trial suggests psilocybin is at least comparable to an SSRI on the primary depression measure and may have advantages in well-being and sexual side effects. Drug scheduling often reflects historical politics more than medical evidence, and this has delayed potentially life-saving therapies.

Data Points: Drug harm criteria: 16 total harms - Nutt’s multi-criteria decision analysis: 9 harms to the user and 7 harms to society. Harms to user: 9 - Part of the drug-harm framework used to rank substances. Harms to society: 7 - Part of the drug-harm framework used to rank substances. Alcohol prevalence: ~80% of American adults and British adults drink - Used to explain why alcohol causes the most societal harm. Most harmful drug overall: Alcohol - Ranked highest in Britain, Europe, and Australia in aggregate harm. Most harmful drugs to the user: Opiates, crack cocaine, crystal meth - Ranked highest when focusing only on harm to the individual. Tobacco ranking: About 6th or 7th overall - Nutt notes tobacco kills many people but later in life and causes less harm to others than alcohol. Ecstasy policy intervention: Free water and chill-out rooms - British harm-reduction measures introduced after ecstasy-related harms were found to be environmental rather than drug-only. LSD research base: 40,000 patients and 1,000 papers - Historical evidence cited for LSD’s therapeutic safety and efficacy before scheduling. LSD grants: 130+ NIH grants - U.S. government-funded research on LSD before prohibition. Psilocybin depression trial dose: 25 mg - High-dose psilocybin used in the NEJM depression study. Psilocybin low-dose comparator: 1 mg - Used as a placebo-like low dose in the blinded psilocybin arm. Psilocybin vs. escitalopram trial duration: 6 weeks - Primary endpoint timing for the depression comparison study. Psilocybin dosing schedule: 2 doses, 3 weeks apart - Study design in the NEJM trial. LSD therapeutic dose: 100–125 micrograms - Typical “big trip” dose used in psychotherapy studies. LSD lower-dose psychotherapy: 25 micrograms - Used weekly in some British psychotherapy protocols. Microdose threshold: >10 micrograms perceptible - Nutt says even 10 micrograms of LSD can be felt. Ketamine antidepressant use: About 30 studies - Evidence base cited for ketamine’s antidepressant effect. Ketamine treatment frequency: Twice a week - S-ketamine (Spravato) dosing discussed as a licensed regimen. Ketamine recreational heavy use: 4–5 times/day; up to 5 grams/day - Associated with bladder damage and cognitive impairment. Fentanyl potency: ~50x heroin - Example of why fentanyl is so dangerous and economically attractive to illicit producers. Carfentanil potency: ~1,000x heroin - Illustrates the extreme potency of super-fentanyls. Alcohol deaths: More people die from opiate overdose than died in the whole Vietnam War (last year cited) - Used to underscore the scale of the opioid crisis. LSD and alcohol use disorder: Potentially 10 million lives saved vs. 2,500 lives saved by prohibition over 50 years - Nutt’s rough estimate comparing therapeutic potential to harms prevented by banning LSD.

Pivotal Quotes: "the most harmful drug overall in all in Europe, in Britain, in Australia is alcohol." — David Nutt: Explaining the aggregate harm rankings from his multi-criteria analysis. "the drugs that have been most vilified and which we've been taught are the most dangerous turn out to be the least dangerous." — David Nutt: Summarizing the paradox that psychedelics rank low on harm despite their stigma. "I think it's the worst censorship of research in the history of the world." — David Nutt: Referring to the banning of LSD and the loss of therapeutic research opportunities.

Implications: Listeners should view drug policy through evidence, not stigma. Psychedelics may become major psychiatric tools, while alcohol and opioids remain the biggest public-health burdens. Better research, safer settings, and rational scheduling could reshape treatment and regulation.